Related references
Note: Only part of the references are listed.Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
Monika M. Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Serum Interleukin 6 Before and After Therapy with Tocilizumab Is a Principal Biomarker in Patients with Rheumatoid Arthritis
Keiko Shimamoto et al.
JOURNAL OF RHEUMATOLOGY (2013)
The problem of choice: current biologic agents and future prospects in RA
Ernest H. Choy et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes
Jung-Yoon Choe et al.
ARTHRITIS RESEARCH & THERAPY (2013)
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon
Sanna Rosengren et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
Y. Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Acute-Phase Serum Amyloid A Regulates Tumor Necrosis Factor α and Matrix Turnover and Predicts Disease Progression in Patients With Inflammatory Arthritis Before and After Biologic Therapy
Mary Connolly et al.
ARTHRITIS AND RHEUMATISM (2012)
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Regulation of Inflammatory Responses in Tumor Necrosis Factor-Activated and Rheumatoid Arthritis Synovial Macrophages by JAK Inhibitors
Anna Yarilina et al.
ARTHRITIS AND RHEUMATISM (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
Keisuke Maeshima et al.
ARTHRITIS AND RHEUMATISM (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
New therapies in the management of rheumatoid arthritis
Maya H. Buch et al.
CURRENT OPINION IN RHEUMATOLOGY (2011)
Influence of Janus Kinase Inhibition on Interleukin 6-mediated Induction of Acute-phase Serum Amyloid A in Rheumatoid Synovium
Kiyoshi Migita et al.
JOURNAL OF RHEUMATOLOGY (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes
Kiyoshi Migita et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
J. H. Coombs et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Selective Functional Inhibition of JAK-3 Is Sufficient for Efficacy in Collagen-Induced Arthritis in Mice
Tsung H. Lin et al.
ARTHRITIS AND RHEUMATISM (2010)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Therapeutic targeting of Janus kinases
Marko Pesu et al.
IMMUNOLOGICAL REVIEWS (2008)
Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis
Yasuaki Okuda et al.
ARTHRITIS AND RHEUMATISM (2006)
Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression
K Hagihara et al.
GENES TO CELLS (2005)
IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system
K Hagihara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Share Paper
